

Participation IUCT-O at ASCO '20

Présentations en symposium

1. Impact of chemotherapy alone or in combination with an anti-angiogenic on the immune tumor microenvironment (TME) of ovarian cancer: Data from the randomized CHIVA trial (a GINECO –GINEGEPS study).

Authors: Elisa Yaniz, Catherine Genestie, Christophe Klein, Flore Salviat, Isabelle Laure Ray-Coquard, Florence Joly, **Gwenael Ferron**, Eric Pujade-Lauraine, Patricia Pautier, Alexandra Leary; Gustave Roussy Cancer center, INSERM U981, Villejuif, France; Gustave Roussy Cancer Center, INSERM U981, Villejuif, France; Centre De Recherche Des Cordeliers, Paris, France; Gustave Roussy Institute, Villejuif, France; GINECO Group and Centre Léon Bérard, Lyon, France; Department of Medical Oncology, Centre François Baclesse, Caen, France; **GINECO and Institut Claudius Regaud, Toulouse, France**; GINECO and Université Paris Descartes, AP-HP, Paris, France; GINECO, French Sarcoma Group and Gustave Roussy Cancer Center, Villejuif, France; Gustave Roussy Cancer Center, Villejuif, France

[Lien vers l'abstract](#)

2. Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.

Authors: Francois Clement Bidard, Celine Callens, **Florence Dalenc**, Barbara Pistilli, Thibault De La Motte Rouge, Florian Clatot, Veronique D'hondt, Luis Teixeira, Helene Vegas, Sibille Everhard, Jerome Lemonnier, Ivan Bieche, **Anne Pradines**, Jean FranCois Paitel, Dominique Spaeth, Isabelle Moullet, Jean-Yves Pierga, Frederique Berger, Anne-Claire Hardy-Bessard, Thomas Bachelot; Centre René Huguenin, Saint Cloud, France; Institut Curie, Paris, France; Department of Medical Oncology, Institut Claudius Regaud–IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Centre Eugène Marquis, Rennes, France; INSERM U1245, IRON Group, Centre Henri Becquerel, University Hospital, University of Normandy, Rouen, France; Institut du Cancer de Montpellier, Montpellier, France; Université de Paris, HIPI INSERM U976, Breast Diseases Unit, AP- HP, Hôpital Saint Louis, Paris, France; Hopital Bretonneau, Tours, France; Unicancer, Paris, France; **Institut Claudius Regaud, IUCT-Oncopole**, Laboratoire de Biologie Médicale Oncologique, Toulouse, France; CHI Fréjus St-Raphaël, Frejus, France; ORACLE, Centre d'Oncologie de Gentilly, Gentilly, France; Clinique de la Sauvegarde, Lyon, France; Biostatistics Unit, INSERM U900, Institut Curie, Paris, France; Medical Oncology Department, CARIO-HPCA and Cooperative Gynecological Cancer Research Group (GINECO), Plerin, France; Centre Léon Bérard, Lyon, France

[Lien vers l'abstract](#)

3. Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.

Authors: Leora Horn, Jennifer G. Whisenant, Valter Torri, Li-Ching Huang, Annalisa Trama, Luis G. Paz-Ares, Enriqueta Felip, **Vera Pancaldi**, Alessandro De Toma, Marcello Tiseo, Pilar Garrido, Carlo Genova, Jacques Cadranet, Olivier Michielin, Anne-Marie C. Dingemans, Jan P. Van Meerbeeck, Fabrice Barlesi, Heather A. Wakelee, Solange Peters, Marina Chiara Garassino; Department of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN; Vanderbilt-Ingram Cancer Center, Nashville, TN; IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; Vanderbilt University Medical Center, Nashville, TN; Istituto

Nazionale dei Tumori, Milan, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; **Centre de Recherche en Cancerologie de Toulouse, Toulouse, France**; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Medical Oncology Unit, University Hospital of Parma, Parma, Italy; University Hospital Ramón y Cajal, Madrid, Spain; Lung Cancer Unit, Ospedale Policlinico San Martino, Genoa, Italy; Service de Pneumologie Hôpital Tenon, Paris, France; Center of Personalized Oncology, Lausanne University Hospital (CHUV), Switzerland, Molecular Modeling Group, Swiss Institute of Bioinformatics, Lausanne, Switzerland; Maastricht University Medical Center, Maastricht, Netherlands; Department of Thoracic Oncology, University Hospital Antwerp, Edegem, Belgium; Aix Marseille University, CNRS, INSERM, Marseille, France; Stanford Cancer Institute, Stanford, CA; Lausanne University Hospital (CHUV), Lausanne University, Lausanne, Switzerland

[Lien vers l'abstract](#)

Présentations orales

1. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.

Authors: Aurelien Marabelle, Philippe Alexandre Cassier, Marwan Fakhri, Steven Chuan-Hao Kao, Dorte Nielsen, Antoine Italiano, Tormod Guren, Marloes Van Dongen, Kristen Renee Spencer, Giovanni M. Bariani, Paolo Antonio Ascierto, Armando Santoro, Sandrine Hiret, Patrick Alexander Ott, Sarina Anne Piha-Paul, Chih-Chin Liu, Melanie A. Leiby, Kevin Norwood, **Jean-Pierre Delord**; Gustave Roussy, Université Paris-Saclay, Villejuif, France; Centre Léon Bérard, Lyon, France; City of Hope National Medical Center, Duarte, CA; Chris O'Brien Lifehouse, Camperdown, NSW, Australia; Herlev Hospital, University of Copenhagen, Copenhagen, Denmark; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France; Oslo University Hospital, Oslo, Norway; Antoni van Leeuwenhoek, Amsterdam, Netherlands; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil; Fondazione IRCCS-Istituto Nazionale dei Tumori, Naples, Italy; Humanitas University, Pieve Emanuele, Italy; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Dana-Farber Cancer Institute, Boston, MA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX; Merck & Co., Inc., Kenilworth, NJ; **Institut Claudius Regaud IUCT- Oncopole, Toulouse, France**

[Lien vers l'abstract](#)

2. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.

Authors: Andreas Du Bois, Jalid Sehouli, Ignace Vergote, **Gwenael Ferron**, Alexander Reuss, Werner Meier, Stefano Greggi, Pernille Tina Jensen, Frederic Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, Elisabeth Avall-Lundqvist, Jae-Weon Kim, Jordi Ponce, Francesco Raspagliesi, Sadaf Ghaem-Maghami, Alexander Reinthaller, Philipp Harter; AGO & Ev. Kliniken Essen-Mitte, Essen, Germany; NOGGO and Charité Campus Virchow-Klinikum, Berlin, Germany; BGOG and University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; **GINECO and Institut Claudius Regaud, Toulouse, France**; AGO &

Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany; AGO and Frauenklinik, Evangelisches Krankenhaus Duesseldorf, Duesseldorf, Germany; MITO & Gynecologic Oncology, Instituto Tumori Fondazione G. Pascale, Naples, Italy; NSGO and Odense University Hospital, Odense, Denmark; Tenon Hospital, Paris, France; GINECO & Institut Bergonie, Bordeaux, France; GINECO and Centre Jean Perrin, Clermont-Ferrand, France; GINECO & Curie Institute, Paris, France; SGOG and Shanghai Fudan University, Shanghai, China; NSGO & Linköping University and Karolinska Institute, Linköping, Sweden; KGOG & Seoul National University, Seoul, South Korea; GEICO and Bellvitge Hospital, Barcelona, Spain; MITO & Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; NCRI and Imperial College London, London, United Kingdom; AGO-Austria and University of Vienna, Vienna, Austria; AGO & Ev. Kliniken Essen-Mitte (PI), Essen, Germany

[Lien vers l'abstract](#)

3. Avelumab in patients with gestational trophoblastic tumors resistant to monotherapy: Final outcomes of TROPHIMMUN phase II trial, cohort A.

Authors: Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, Jerome Massardier, **Laurence Gladieff**, Florence Joly, Touria Hajri, Delphine Maucourt-Boulch, Sylvie Bin, Pascal Rousset, Laurent Villeneuve, Adeline Roux, Marine Alves-Ferreira, Daniele Grazziotin, Catherine Mercier, Gilles Freyer, Francois Golfier; Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, EMR UCBL/HCL 3738, Lyon, GINECO & GINEGEPS, Lyon, France; Centre de Référence des Maladies Trophoblastiques, Hospices Civils de Lyon, Lyon, France; Hôpital Tenon, Paris, France; **GINECO, Institut Claudius Regaud, Toulouse, France; Department of Medical Oncology**, Centre François Baclesse, Caen, France; Centre de Référence des Maladies Trophoblastiques, Lyon, France; Hospices Civils de Lyon, Lyon, France; Hospice Civils Lyon Unite Rechercher Clinique Pole Information Medicale, Lyon, France; APREC, Hospital Tenon (AP-HP), Paris, France; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre de Référence des Maladies Trophoblastiques, Centre Hospitalier Lyon-Sud, EMR3738, Université Lyon 1, Lyon, France

[Lien vers l'abstract](#)

4. A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.

Authors: Patricia Pautier, Anne Floquet, **Christine Chevreau**, Nicolas Penel, Cecile Guillemet, Corinne Delcambre, Didier Cupissol, Frederic Selle, Nicolas Isambert, Sophie Piperno-Neumann, Esma Saada-Bouzi, Francois Bertucci, Emmanuelle Bompas, Pascaline Boudou-Rouquette, Olivier Collard, Valérie Le Brun Ly, Maud Toulmonde, Axel Le Cesne, Benjamin Lacas, Florence Duffaud; Medical Oncology Department, Institut Gustave Roussy, Villejuif, France; Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France; **IUCT-Oncopôle/Institut Claudius Regaud, Toulouse, France**; Department of Medical Oncology, Centre Oscar Lambret, Lille, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Tenon Hospital, Paris, France; Centre Georges-François Leclerc, Dijon, France; Medical Oncology Department, Institut Curie, Paris, France; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France; Institut Paoli-Calmettes, Marseille, France; Centre René Gauducheau, Nantes, France; Department of Medical Oncology, Cochin Hospital, Paris University, Paris, France; Institut de Cancérologie de la Loire, St. Priest En Jarez, France; Centre Hospitalo-Universitaire

Dupuytren, Limoges, France; Institut Bergonié, Department of Medical Oncology, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Gustave Roussy, Villejuif, France; La Timone University Hospital, Marseille, France

[Lien vers l'abstract](#)

5. **PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.**

Authors: Antonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, **Florence Dalenc**, Miguel J. Gil Gil, Manuel Ruiz Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Serena Di Cosimo, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez-De Dueñas, Kepa Amillano, Javier Cortes; Hospital Arnau de Vilanova, Universidad Católica, Medica Scientia Innovation Research (MedSIR), Valencia, Spain; IOB, Institute of Oncology, QuironSalud Group, Madrid and Barcelona, Medica Scientia Innovation Research (MedSIR) Barcelona, Spain and Ridgewood, New Jersey, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Medical Oncology, **Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France**; Breast Cancer Unit & Medical Oncology Department, Institut Català d'Oncologia, IDIBELL, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Seville, Spain; Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona and Ridgewood, Barcelona, Spain; Barts ECMC, Barts Cancer Institute, Queen Mary University of London, and Barts Hospital NHS Trust, London, United Kingdom; Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für Tumorerkrankungen und Universitätsfrauenklinik Heidelberg, Heidelberg, Germany; Biomarker Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Medical Oncology Department Tenon Hospital, Paris, France; University Hospital Heidelberg, Heidelberg, Germany; Medical Oncology, Hospital del Mar, Barcelona, Spain; Hospital Universitario La Paz, Medical Oncology Department, Madrid, Spain; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Hospital Provincial Castellón, Servicio de Oncología, Castelló De La Plana, Spain; Hospital Universitari Sant Joan de Reus, Reus, Spain; IOB Institute of Oncology, QuironSalud Group, Madrid and Barcelona, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Medica Scientia Innovation Research (MedSIR), Barcelona and Ridgewood, Barcelona, Spain

[Lien vers l'abstract](#)

6. **Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.**

Authors: Javier Cortes, Geraldine Gebhart, Manuel Ruiz Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escrivá, Lourdes Calvo Martínez, Nuria Ribelles, Noelia Martinez, Cinta Albacar, Aleix Prat, **Florence Dalenc**, Kerrou Khaldoun, Peter Schmid, Marco Colleoni, Frederik Marmé, Noemia Afonso, Miguel Sampayo-Cordero, José Manuel Pérez-García, Antonio Llombart-Cussac; IOB Institute of Oncology, Hospital Quirónsalud, Medica Scientia Innovation Research, and Vall d'Hebron University of Oncology, Barcelona, Spain; Institut Jules Bordet–Université Libre de Bruxelles, Brussels, Belgium; Hospital Universitario Virgen del Rocío, Seville, Spain; Institut Català d'Oncologia Hospital Duran I Reynals, Barcelona,

Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; Medical Oncology Department, Breast Cancer Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Hospital Universitario A Coruña, A Coruña, Spain; UGC Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria de Malaga, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain; University Hospital Ramón y Cajal, Madrid, Spain; Hospital Universitari Sant Joan de Reus, Reus, Spain; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; **Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France**; Nuclear Medicine and PET center Dept- APHP, Tenon Hospital IUC-UPMC, Sorbonne University, Paris, France; Barts ECOM, Barts Cancer Institute, Queen Mary University of London, and Barts Hospital NHS Trust, London, United Kingdom; Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy; Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für Tumorerkrankungen und Universitätsfrauenklinik Heidelberg, Heidelberg, Germany; Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal; Medica Scientia Innovation Research (MedSIR), Barcelona and Ridgewood, Barcelona, Spain; IOB, Institute of Oncology, QuironSalud Group, Madrid and Barcelona, Medica Scientia Innovation Research (MedSIR) Barcelona, Spain and Ridgewood, New Jersey, Barcelona, Spain; Hospital Arnau de Vilanova, Universidad Católica, Medica Scientia Innovation Research (MedSIR), Valencia, Spain
[Lien vers l'abstract](#)

7. REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.

Authors: Sophie Cousin, Carine A. Bellera, Jean Philippe Guégan, **Carlos A. Gomez-Roca**, Jean-Philippe Metges, Antoine Adenis, Simon Pernot, Coralie Cantarel, Michèle Kind, Maud Toulmonde, Kevin Bourcier, Isabelle Soubeyran, Alban Bessedé, Antoine Italiano; Department of Medicine, Institut Bergonié, Bordeaux, France; INSERM CIC 14.01 Bordeaux, Clinical Epidemiology Unit, Bordeaux, France; Immusmol, Bordeaux, France; **Institut Universitaire du Cancer de Toulouse—Oncopole, Toulouse, France**; Centre Hospitalier Régional Universitaire (CHRU) de Brest—Hopital Morvan, Brest, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Institut Bergonié, Department of Imaging, Bordeaux, France; Institut Bergonié, Department of Medical Oncology, Bordeaux, France; Bergonie Institute, Bordeaux, France; ImmuSmol, Bordeaux, France; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France
[Lien vers l'abstract](#)

8. Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.

Authors: Angelina Tjokrowidjaja, Chee Khoo Lee, Michael Friedlander, Val GebSKI, **Laurence Gladieff**, Jonathan A. Ledermann, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Luis Manso, Carmela Pisano, Rebecca Asher, Nicoletta Colombo, Tjoung-Won Park-Simon, Keiichi Fujiwara, Gabe S. Sonke, Ignace Vergote, Jae-Weon Kim, Eric Pujade-Lauraine; NHMRC Clinical Trials Centre, Camperdown, NSW, Australia; NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, Australia; The Prince of Wales Hospital, Randwick, Sydney, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; **GINECO, Institut Claudius Regaud, Toulouse, France**; University College London Cancer Institute, London, United Kingdom; Massachusetts General Hospital, Boston, MA;

Princess Margaret Cancer Centre, Toronto, ON, Canada; ISGO & Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; GEICO & Hospital 12 de Octubre, Madrid, Spain; MITO & Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy; NHMRC CTC Centre, University of Sydney, Camperdown, Sydney, Australia; MANGO and European Institute of Oncology, Milan, Italy; Department of Gynaecology and Obstetrics, Hannover Medical School, Hannover, Germany; Saitama Medical University International Medical Center, Hidaka, Japan; DGOG and Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands; BGOG and University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Seoul National University, Seoul, South Korea; GINECO and Université Paris Descartes, AP-HP, Paris, France
[Lien vers l'abstract](#)

9. Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).

Authors: Jennifer Keating Litton, Douglas Laird, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, **Henri Roche**, Young-Hyuck Im, Annabel Goodwin, Joanne Lorraine Blum, Wolfgang Eiermann, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Lee A. Albacker, Garrett M. Frampton, Lida A. Mina; The University of Texas MD Anderson Cancer Center, Houston, TX; Pfizer Inc., San Francisco, CA; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; University of California, Los Angeles/Jonsson Comprehensive Cancer Center (UCLA/JCCC), Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain; **Institut Universitaire du Cancer de Toulouse, Toulouse, France**; Samsung Medical Center, Seoul, South Korea; Concord Clinical School, University of Sydney, NSW, Australia; Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; Interdisziplinäres Onkologisches Zentrum München, Munich, Germany; Pfizer Inc., San Diego, CA; Pfizer Inc, Milan, Italy; Pfizer Inc., Cambridge, MA; Foundation Medicine, Inc., Cambridge, MA; Banner MD Anderson Cancer Center, Gilbert, AZ
[Lien vers l'abstract](#)

Présentations posters

1. Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).

Authors: Enrique M. Ocio, Paula Rodríguez Otero, Sara Bringham, Stefania Oliva, Axel Nogai, **Michel Attal**, Philippe Moreau, Joaquin Martinez-Lopez, Nadia Le Roux, Sandrine Macé, Marie-Claude Rouchon, Qiuyan Wang, Maria-Victoria Mateos; Marqués de Valdecilla University Hospital (IDIVAL), University of Cantabria, Santander, Spain; University Clinic of

Navarra, Center for Applied Medical Research (CIMA), IDISNA, Pamplona, Spain; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy; Division of Hematology and Oncology at Campus Benjamin Franklin (CBF), Charité, Berlin, Germany; **Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France**; Hematology Department, CHU Nantes, Nantes, France; Hematology, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense de Madrid, Madrid, Spain; Sanofi Oncology Development, Vitry-Sur-Seine, France; Sanofi Translational Medicine and Early Development, Montpellier, France; Sanofi, Beijing, China; University Hospital of Salamanca/IBSAL/Cancer Research Center- IBMCC (USAL-CSIC), Salamanca, Spain

[Lien vers l'abstract](#)

2. Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057.

Authors: Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward M. Uchio, Joost L. Boormans, Dean F. Bajorin, **Mathieu Roumiguié**, Eric A. Singer, Laurence Eliot Miles Krieger, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Kijoeng Nam, João Paulo Zambon, Ekta Kapadia, Ronald De Wit; Perlmutter Cancer Center, NYU Langone Health, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX; Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada; UCI Health, Orange, CA; Erasmus MC, Rotterdam, Netherlands; Memorial Sloan Kettering Cancer Center, New York, NY; **Institut Universitaire du Cancer Toulouse Oncopole CHU, Toulouse, France**; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Royal North Shore Hospital, Northern Cancer Institute, St Leonards, NSW, Australia; University of Washington, Seattle, WA; National Cancer Center, Goyang, South Korea; University of Tsukuba, Tsukuba, Japan; University of Minnesota, Minneapolis, MN; Merck & Co., Inc., Kenilworth, NJ

[Lien vers l'abstract](#)

3. Final results of the multicenter, open-label, randomized phase II trial PAZOTHYR evaluating continuous versus intermittent administration of pazopanib in radio-iodine-refractory thyroid cancers (NCT01813136).

Authors: Christelle De La Fouchardiere, Yann Godbert, Cécile Dalban, Christine Do Cao, Frederic Illouz, **Slimane Zerdoud**, Johanna Wassermann, Stephane Bardet, Patrice Rodien, Cecile N Chougnet, Danielle Benisvy, Patricia Niccoli, Alain Ravaud, William Lebosse, Valérie Bourne-Branchu, Julien Gautier, Sophie Leboulleux, Tuthyref; Leon Berard Cancer Centre, Lyon, France; Bergonié Institute Cancer center, Bordeaux, France; Centre Léon Bérard, Lyon, France; CHRU, Lille, France; CHU d'Angers, Angers, France; **Institut Universitaire du cancer Toulouse Oncopole, Toulouse, France**; Pitié-Salpêtrière Hospital, Sorbonne University, Cancer University Institute, Paris, France; CLCC-Institut François Baclesse, Caen, France; Hôpital Saint Louis, Paris, France; Centre Antoine Lacassagne, Nice, France; Institut Paoli Calmette, Marseille, France; CHU Hopitaux de Bordeaux-Hôpital Saint-André, Bordeaux, France; Centre Leon Berard, Lyon, France; Institut Gustave Roussy, Villejuif, France

[Lien vers l'abstract](#)

4. Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO Trial).

Authors: Jean Marc Schiano de Colella, Simonetta Viviani, Davide Rapezzi, CATERINA PATTI, Lauriane Clement Filliatre, Andrea Rossi, Fontanet Bijou, Maria Cantonetti, **Cécile Borel**, Brice

Thamphya, Renaud Schiappa, Emmanuel Chamorey, Colin Debaigt, Lauris Gastaud, Antoine Thyss, Andrea Gallamini; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy; Ospedale S. Croce e Carle Cuneo, Cuneo, Italy; Aoor Villa Sofia Cervello, Palermo, Italy; CHU de Nancy, Nancy, France; Asst Papa Giovanni XXIII Bergamo, Bergamo, Italy; Institut Bergonié, Bordeaux, France; Fondazione Policlinico Tor Vergata, Rome, Italy; **Institut Universitaire du Cancer de Toulouse, Toulouse Cedex, France**; Centre Antoine Lacassagne, Nice, France; Biostatistics' Unite, Antoine Lacassagne Cancer Center, University of Cote d'Azur, Nice, France; Antoine- Lacassagne Cancer Center, Nice, France

[Lien vers l'abstract](#)

5. Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

Authors: Charles Herbaux, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Reda Bouabdallah, Stephanie Guidez, **Loic Ysebaert**, Herve Tilly, Steven Le Gouill, Luc Fornecker, Nicolas Daguindau, Nadine Morineau, Corinne Haioun, Emmanuel Gyan, David Sibon, Rémy Gressin, Roch Houot, Gilles A. Salles, Franck Morschhauser, Guillaume Cartron; Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille, France; CHU Dijon, Dijon, France; Department of Hematology, CHU Nancy, Nancy, France; Department of Hematology, University Hospital, School of Medicine, Caen, France; Institut Paoli-Calmettes, Marseille, France; Poitiers University Hospital/INSERM CIC 1402, Poitiers, France; Department of Haematology, **Institut Universitaire du Cancer de Toulouse— Oncopôle, Toulouse, France**; Department of Hematology, Centre Henri Becquerel, University of Rouen, Rouen, France; CHU Nantes and UMR892 INSERM, Nantes, France; University Hospital of Strasbourg, Strasbourg, France; Hématologie clinique CH Annecy Genevois, Annecy, France; CHD Vendée, Hematology, La Roche-sur- Yon, France; Henri Mondor University Hospital, University Hospital, Créteil, France; CHU de Tours-Hôpital Bretonneau, Tours Cedex, France; Hôpital Necker-Enfants Malades Hematology, Paris, France; Université Grenoble Alpes, Institut Albert Bonniot, Departement d'Hématologie Clinique, Centre Hospitalier et Universitaire de Grenoble- Alpes, Grenoble, France; Centre Hospitalier Universitaire Pontchaillou, Rennes, France; Centre Hospitalier Lyon Sud, Pierre Bénite, France; CHU Lille-Hopital Claude Huriez, Lille, France; CHU de Montpellier, Montpellier, France

[Lien vers l'abstract](#)

6. Histopathologic validation of the sentinel node technique in early-stage cervical cancer patients.

Authors: Patrice Mathevet, Benedetta Guani, Andrea Ciobanu, **Eliane Mery Lamarche**, Florent Boutitie, Vincent Balaya, Fabrice Lecuru; University Hospital of Lausanne, Lausanne, Switzerland; Hôpitaux du Lemman, Thonon Les Bains, France; **IUCT Oncopole, Toulouse, France**; CHU Lyon, Lyon, France; Paris Descartes University, Paris, France; GINECO & Curie Institute, Paris, France

[Lien vers l'abstract](#)

7. Nationwide incidence of sarcomas and tumors of intermediate malignancy in the NETSARC network with central pathology review: Correlation with published clinical research.

Authors: Gonzague De Pinieux, Marie Karanian, Francois Le Loarer, **Sophie Le Guellec**, Philippe Terrier, Corinne Bouvier, Maxime Battistella, Yves Marie Robin, Jean-François Emile,

Anne Moreau, Frederique Larousserie, Agnès Leroux, Nathalie Stock, Marick Laé, Françoise Collin, Antoine Italiano, Axel Le Cesne, Nicolas Penel, Jean Michel Coindre, Jean-Yves Blay, on behalf of the RREPS/RESOS/NETSATC (NETSARC+) and French Sarcoma Group-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) Networks; Hopital Trousseau, Tours, France; Department of Pathology, Centre Leon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; **Institut Universitaire du Cancer-Oncopole, Toulouse, France**; Gustave Roussy Cancer Campus, Villejuif, France; Assistance Publique-Hopitaux De Marseille, Marseille, France; Department of Pathology, Saint Louis Hospital, APHP, Paris, France; Centre Oscar Lambret, Lille, France; Ambroise Paré Hospital, Versailles University, Boulogne, France, Boulogne, France; Nantes University Hospital, Nantes, France; Hôpital Cochin AP-HP, Paris, France; Centre Alexis Vautrin, Pathology and Tumor Biology Dept, EA4421 SiGrETO Nancy University, Vandoeuvre-lès- Nancy, France; CHU Rennes, Rennes, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Early Phase Trials Unit, Institut Bergonié, Bordeaux, France; Institut Gustave Roussy, Villejuif, France; Department of Medical Oncology, Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Unicancer, Lyon, France
[Lien vers l'abstract](#)

8. Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

Authors: Barbara Pistilli, Hans Wildiers, Erika Paige Hamilton, Ana Alexandra Ferreira, **Florence Dalenc**, Maria Vidal, Joaquín Gavilá, Anthony Goncalves, Carmen Murias, Marie-Ange Mouret-Reynier, Jean-Luc Re Canon, Fernando Bazan, Sylvain Ladoire, L. Andres Sirulnik, Mohamed Bekradda, Kees Bol, Viktoriya Stalbovskaia, Anastasia Murat, Jim Ford, Francois Clement Bidard; Gustave Roussy, Villejuif, France; University Hospitals Leuven, Leuven, Belgium; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Instituto Português de Oncologia-Porto, Porto, Portugal; Department of Medical Oncology, **Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France**; Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain; Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Institut Paoli-Calmettes, Marseille, France; Sarah Cannon Research Institute, London, United Kingdom; GINECO-Centre Jean Perrin, Clermont- Ferrand, France; Department of Oncology-Hematology, Grand Hôpital de Charleroi, Charleroi, Belgium; CHU Minjoz, Besançon, France; Dpt of Medical Oncology, Centre Georges-François Leclerc, Dijon, France; Merus NV, Utrecht, Netherlands; Oncology Therapeutic Development, Clichy, France; Merus N.V., Utrecht, Netherlands; Centre René Huguenin, Saint Cloud, France
[Lien vers l'abstract](#)

9. Results of a prospective phase II national study: Prophylactic radical fimbriectomy (NCT01608074), in women with a documented high risk of breast/ovarian cancer—Final pathological results and outcomes.

Authors: Eric Leblanc, Fabrice Narducci, Delphine Hudry, Audrey Mailliez, Anne-Sophie Lemaire, Emmanuelle Tresch-Bruneel, Michel Salzet, Christophe Pomel, Frederic Caquant, Gilles Houvenaeghel, Jean-Yves Charvolin, Agathe Crouzet, Frederic Guyon, Yves Fouche, **Gwenael Ferron**, Sebastien Gouy, Veronique Vaini-Cowen, Virginie Fourchette, Francois Golfier, Pierre Collinet; Centre Oscar Lambret, Lille, France; PRISM Laboratory Inserm U1192, Lille, France; Centre Jean Perrin, Clermont Ferrand, France; Clinique du Parc, Croix, France; Aix-Marseille Univ, Institut Paoli-Calmettes, Marseille, France; Clinique du Bois, Lille, France;

Centre Henri Becquerel, Rouen, France; GINECO & Institut Bergonie, Bordeaux, France; Centre Antoine Lacassagne, Nice, France; **GINECO and Institut Claudius Regaud, Toulouse, France**; Department of Surgery, Gustave Roussy Cancer Centre, Villejuif, France; Polyclinique du Parc Rambot, Aix En Provence, France; Institut Curie, Paris, France; Centre de Reference des Maladies Trophoblastiques, Centre Hospitalier Lyon-Sud, EMR3738, Université Lyon 1, Lyon, France; CHRU, Lille, France

[Lien vers l'abstract](#)

10. Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.

Authors: Cyrille Touzeau, Philippe Moreau, **Aurore Perrot**, Cyrille Hulin, Mamoun Dib, Mourad Tiab, Denis Caillot, Thierry Facon, Xavier Leleu, Niels W.C.J. van de Donk, Annemiek Broijl, Sonja Zweegman, Mark-David Levin, Michel Delforge, Lixia Pei, Veronique Vanquickenberghe, Carla De Boer, Tobias Kampfenkel, Jessica Vermeulen, Pieter Sonneveld, on behalf of IFM and HOVON; Centre Hospitalier Universitaire, Nantes, France; Hematology, University Hospital Hôtel-Dieu, Nantes, France; **Hematology Department, University Cancer Institute IUCT, Toulouse, France**; Department of Hematology, Hôpital Haut Lévêque, University Hospital Bordeaux, Pessac, France; CHRU- Hôpital du Bocage, Angers, France; CHD Vendée, La Roche-sur-Yon, France; CHU Dijon, Hôpital Du Bocage, Dijon, France; University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; CHU Poitiers-Hôpital la Milétrie, Poitiers, France; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, Netherlands; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Albert Schweitzer Hospital, Dordrecht, Netherlands; Universitaire Ziekenhuizen Leuven, Leuven, Belgium; Janssen Research & Development, LLC, Raritan, NJ; Janssen Research & Development, Beerse, Belgium; Janssen Research & Development, LLC, Leiden, Netherlands

[Lien vers l'abstract](#)

11. Efficacy of imiquimod in the management of lentigo maligna.

Authors: Brigitte Dréno, Monica Dinulescu, Jean-Michel NGuyen, Hevé Maillard, Florence Le Duff, Laurent Machet, Marie Beylot-Barry, Delphine Legoupil, Ewa Wierzbicka-Hainaut, Christophe Bedane, Marie Thérèse Leccia, Sébastien Debarbieux, **Nicolas Meyer**, Sandrine Monestier, Guido Bens, Marc G. Denis, Celine Bossard, Beatrice Vergier, Amir Khammari; Department of Dermatology-Oncology, Nantes University, CHU Nantes, CIC1413, CRCINA, Nantes, France; Dermatology, CHU Rennes, Rennes, France; Biostatistic Department, PIMESP, St Jacques Hospital, Nantes, France; Dermatology, CH Le Mans, Le Mans, France; Dermatology department,, Nice, France; Dermatology department, CHRU, Inserm U-1253, University of Tours, France, Tours, France; Dermatology, Hôpital Saint-André, CHU de Bordeaux, Université de Bordeaux, Bordeaux, France; Dermatology department, CHRU Brest, Brest, France; Dermatology, CHU Miletrie, Poitiers, France; Dermatology department, CHU Limoges., Limoges, France; Dermatology department, CHU Albert Michalon, Grenoble; Université de Grenoble, Grenoble, France; Centre Hospitalier Lyon Sud, Lyon, France; **IUCT-Oncopole, Toulouse, France**; Dermatology department, AP-HM., Marseille, France; Dermatology department, CHR Orleans., Orleans, France; Department of Biochemistry, Nantes University Hospital, Nantes, France; Pathology Department, CHU Hotel Dieu and CRCINA, INSERM U1232, Nantes, France; CHU Bordeaux-Université Bordeaux, INSERM U1053, Team 3, Bordeaux, France; Dermato-Oncology Department, Nantes University,

Nantes, France

[Lien vers l'abstract](#)

12. Clinical outcome of patients experiencing central nervous system progression on first-line pertuzumab and trastuzumab for HER2-positive metastatic breast cancer in a real-life cohort.

Authors: Laetitia Collet, Lauriane Eberst, Julien Fraisse, Marc Debled, Christelle Levy, Marie-ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Veronique Dieras, Thierry Petit, Gaetane Simon, Marianne Leheurteur, **Florence Dalenc**, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot; Centre Léon Bérard, Lyon, France; Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Department of Medical Oncology, Caen, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Georges-François Leclerc, Dijon, France; Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France; Institut Curie, Paris & Saint-Cloud, France; Centre Eugène Marquis, Rennes, France; Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France; Unicancer, Paris, France; Centre Henri Becquerel, Rouen, France; **Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France**; Centre Oscar Lambret, Lille, France; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France; Gustave Roussy Cancer Campus, Villejuif, France

[Lien vers l'abstract](#)

13. Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma: The GINECO- UTOLA study.

Authors: Florence Joly, Pierre Emmanuel Brachet, Sophie Abadie Lacourtoisie, Bernard Asselain, Anne Floquet, Olivier Collard, Manuel Rodrigues, Karen Leroy, Corinne Jeanne, Alexandra Leary, **Sarah Betrian**, Benoit You, Yolanda Fernandez Diez, Anne-Claire Hardy-Bessard, Annick Chevalier, Elsa Kalbacher, Corina Cornila, Cyril Foa, Philippe Follana, Jerome Alexandre; Department of Medical Oncology, Centre François Baclesse, Caen, France; Centre François Baclesse, Caen, France; ICO Paul Papin, Angers, France; ARCAGY-GINECO, Paris, France; Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Bordeaux, France; Institut de Cancérologie de la Loire, St. Priest En Jarez, France; Medical Oncology Department, Institut Curie, Paris, France; AP-HP.Centre, hôpital COCHIN, Paris Université Paris Descartes, faculté de médecine, Paris, France; Gustave Roussy Cancer Center, Villejuif, France; **Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France**; Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, EMR UCBL/HCL 3738, Lyon, GINECO & GINEGEPS, Lyon, France; ICL Institut de Cancérologie de Lorraine, Vandoeuvre LES Nancy, France; Medical Oncology Department, CARIO-HPCA and Cooperative Gynecological Cancer Research Group (GINECO), Plerin, France; Département d'Oncologie Médicale, Centre Oscar-Lambret, Lille, France; CHU Besançon, Besançon, France; Centre Hospitalier Régional d'Orléans, Orleans, France; Hôpital Saint Joseph-Service d'Oncologie Médicale, Marseille, France; Centre Antoine Lacassagne, Nice, France; Cochin Port Royal Hospital, AP-HP, Paris Descartes University, CARPEM, Paris, France

[Lien vers l'abstract](#)

14. Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2

amplified Authors: Erika Paige Hamilton, Thierry Petit, Barbara Pistilli, Anthony Goncalves, Ana Alexandra Ferreira, **Florence Dalenc**, Fatima Cardoso, Monica M. Mita, Vincent O. Dezentjé, Luis Manso, Stephanie L. Graff, Francois Clement Bidard, Philippe Georges Aftimos, Santiago Escrivá, Noemia Afonso, Ernesto Wasserman, Kees Bol, Viktoriya Stalbovskaya, Anastasia Vliet, Thomas Bachelot; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France; Gustave Roussy, Villejuif, France; Institut Paoli-Calmettes, Marseille, France; Instituto Português de Oncologia-Porto, Porto, Portugal; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France; Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, Netherlands; GEICO & Hospital 12 de Octubre, Madrid, Spain; Sarah Cannon Cancer Institutes HCA Midwest Health, Overland Park, KS; Centre René Huguenin, Saint Cloud, France; Institut Jules Bordet, Brussels, Belgium; Medical Oncology Department, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Merus NV, Utrecht, Netherlands; Merus N.V., Utrecht, Netherlands; Centre Léon Bérard, Lyon, France

[Lien vers l'abstract](#)

15. Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.

Authors: Srikala S. Sridhar, Michael Paul Kolinsky, Gwenaëlle Gravis, **Loïc Mourey**, Jose Maria M. Piulats Rodriguez, Emanuela Romano, William R. Berry, Howard Gurney, Margitta Retz, Leonard Joseph Appleman, Martin Boegemann, Johann S. De Bono, Anthony M. Joshua, Urban Emmenegger, Henry Jacob Conter, Brigitte Laguerre, Haiyan Wu, Ping Qiu, Charles Schloss, Evan Y. Yu; Princess Margaret Cancer Centre, Toronto, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Institut Paoli-Calmettes, Paris, France; **Institut Universitaire du Cancer–Oncopole, Toulouse, France**; Catalan Institute of Oncology, Barcelona, Spain; Center for Cancer Immunotherapy, Institut Curie, Paris, France; Duke Cancer Center Cary, Cary, NC; Macquarie University Hospital, Sydney, NSW, Australia; Rechts der Isar University Hospital, Technical University of Munich, Munich, Germany; UPMC, Pittsburgh, PA; University Hospital Muenster, Münster, Germany; The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom; Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; Sunnybrook Research Institute, Toronto, ON, Canada; University of Western Ontario, Brampton, ON, Canada; Centre Eugène Marquis, Rennes, France; Merck & Co., Inc., Kenilworth, NJ; University of Washington, Seattle, WA

[Lien vers l'abstract](#)

16. Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

Authors: Henry Jacob Conter, Neal D. Shore, William R. Berry, Peter C.C. Fong, Jose Maria M. Piulats Rodriguez, Leonard Joseph Appleman, Tilman Todenhöfer, Gwenaëlle Gravis, Brigitte

Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, **Loic Mourey**, Johann S. De Bono, Audrey E. Kam, Urban Emmenegger, Haiyan Wu, Ping Qiu, Charles Schloss, Evan Y. Yu; University of Western Ontario, Brampton, ON, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Duke Cancer Center Cary, Cary, NC; Auckland City Hospital, Auckland, New Zealand; Catalan Institute of Oncology, Barcelona, Spain; UPMC, Pittsburgh, PA; Studienpraxis Urologie, Nürtingen, Germany; Institut Paoli- Calmettes, Paris, France; Centre Eugène Marquis, Rennes, France; Macquarie University Hospital, Sydney, NSW, Australia; Rechts der Isar University Hospital, Technical University of Munich, Munich, Germany; Center for Cancer Immunotherapy, Institut Curie, Paris, France; **Institut Universitaire du Cancer– Oncopole, Toulouse, France**; The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom; Rush University Medical Center, Chicago, IL; Odette Cancer Centre, Toronto, ON, Canada; Merck & Co., Inc., Kenilworth, NJ; University of Washington, Seattle, WA

[Lien vers l'abstract](#)

Publication

1. The impact of patients' and physicians' characteristics on surgery decision for head and neck cancer: Results of a national survey

Authors: **Agnès Dupret-Bories, Pascale Grosclaude**, Sebastien Lamy, Antoine Nebout, **Pierre Bories, Fanny Cros**; **Institut Claudius Regaud, Toulouse, France**; **UMR 1027, Inserm University of Toulouse 3 Paul Sabatier, Team Equity, Toulouse, France**; **University of Toulouse III Paul Sabatier, Toulouse, France**; Université Paris-Saclay, INRA, Research Unit 1303 ALISS, Paris, France; **ONCOMIP Cancer Healthcare Network, Toulouse Cedex 9, France**; **CHU Toulouse, Toulouse, France**

[Lien vers l'abstract](#)

IUCT Purpan, IUCT Rangueil/Larrey

Présentation orale

1. KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).

Authors: Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csósz, Parneet Kaur Cheema, Delvys Rodriguez-Abreu, Mira Wollner, Grzegorz Czyzewicz, James Chih-Hsin Yang, **Julien Mazieres**, Francisco J Orlandi, Alexander Luft, Mahmut Gumus, Terufumi Kato, Gregory Peter Kalemkerian, Yiwen Luo, Maria Catherine Pietanza, Hye Ryun Kim; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Medical Oncology Department, Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Meir Medical Center, Kfar-Saba, Israel; Lausanne University Hospital, Lausanne, Switzerland; Hetenyi G Korhaz, Onkológiai Kozpont, Szolnok, Hungary; William Osler Health System, University of Toronto, Brampton, ON, Canada; Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas De Gran Canaria, Spain; Rambam Medical Center, Haifa, Israel; John Paul II Hospital, Kraków, Poland; National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; **Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France**; Oncología-Health and Care, Santiago, Chile; Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation; Istanbul Medeniyet University Hospital, Istanbul, Turkey; Kanagawa Cancer Center, Kanagawa, Japan; University of Michigan, Ann Arbor, MI; Merck & Co., Inc, Kenilworth, NJ; Yonsei Cancer Center, Seoul, South Korea
[Lien vers l'abstract](#)

Présentations posters

1. Tag-n-trak study: Preliminary analysis of an unselected biobank tumors with NTRK fusion transcript, the French SFCE society contribution.

Authors: Lauriane Lemelle, Delphine Guillemot, Hervé Brisse, Arnaud Gauthier, Matthieu Carton, Anne-Laure Hermann, Nadege Corradini, Angélique Rome, Hélène Boutroux, Anne Jourdain, Aude Marie Cardine, Sarah Jannier, **Marie Pierre Castex**, Anne Sophie Defachelles, Isabelle Aerts, Marie Karanian, Francois P. Doz, Olivier Delattre, Gaëlle Pierron, Daniel Orbach; SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, PSL University, Paris, France; Department of Somatic Genetics, Institut Curie, Paris, France; Imaging Department, Institut Curie, Paris, France; Department of Pathology, Institut Curie, Paris, France; Department of Biostatistics, Institut Curie, PSL University, Paris, France; Department of Radiology, Armand Trousseau Hospital, Paris, France; Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France; Centre Hospitalier Universitaire, Department of Pediatric Oncology, Marseille, France; Centre Hospitalier Universitaire, Department of Pediatric Onco-hematology, Hôpital Trousseau, AP-HP, Paris, France; Department of Pediatric Oncology and Haematology, University Hospital of Tours, Tours, France; Pediatric Immuno-Hematology-Oncology Unit, University Hospital of Rouen, Rouen, France; Pediatric Oncology Department, CHU Hautepierre, Strasbourg, France; Department of Paediatric Oncology,

Centre Hospitalo-Universitaire de Toulouse, Paul Sabatier University Toulouse III, Toulouse, France; Department of Pediatric Oncology, Oscar Lambret Center, Lille, France; Department of Pathology, Centre Leon Bérard, Lyon, France

[Lien vers l'abstract](#)

2. Prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC.

Authors: Jose Carlos Benitez, Marie Eve Boucher, Eric Dansin, Mallorie Kerjouan, **Julien Mazieres**, Eric Pichon, Francois Thillays, Pierre-Emmanuel Falcoz, Benoit Roch, Youssef Oulkhour, Calcagno Fabien, Luc Thiberville, Christelle Clément Duchene, Franck Morin, Pascale Missy, Pascal Alexandre Thomas, Jean-Michel Maury, Thierry Molina, Nicolas Girard, Benjamin Besse; Gustave Roussy, Villejuif, Paris, YT, France; Medical Oncology Department, Gustave Roussy, Villejuif, France; Centre Oscar Lambret, Lille, France; CHU Rennes, Rennes, France; **IUCT, CHU de Toulouse, Toulouse, France;** Centre Hospitalier Universitaire Tours, Tours, France; ICO René Gauducheau, Pays-De-La-Loire, France; Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France; Centre Hospitalier Universitaire de Montpellier, Montpellier, France; Centre Hospitalier Universitaire de Caen, Caen, France; IRFC-CHRU Besançon, Besançon, France; Centre Hospitalier Unversitaire Rouen, Rouen, France; Institut de Cancérologie de Lorraine, Nancy, France; Intergroupe Francophone de Cancérologie Thoracique, Paris, France; Centre Hospitalier Universitaire Marseille, Marseille, France; Institut Curie, Paris, France; APHP, Paris, France; Gustave Roussy Université Paris Sud, Villejuif, France

[Lien vers l'abstract](#)

3. Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non- small cell lung cancer (NSCLC): A phase Ib, multicenter, study.

Authors: Hossein Borghaei, Benjamin Besse, Aditya Bardia, **Julien Mazieres**, Sanjay Popat, Bincy Augustine, Anthony Michael D'amelio, Daniel Barrios, Hope S. Rugo; Fox Chase Cancer Center, Philadelphia, PA; Gustave Roussy Université Paris Sud, Villejuif, France; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; **Toulouse University Hospital, and Paul Sabatier University, Toulouse, France;** Royal Marsden Hospital, London, United Kingdom; Daiichi Sankyo Inc., Basking Ridge, NJ; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

[Lien vers l'abstract](#)

4. Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

Authors: David Planchard, Benjamin Besse, Harry Groen, Sayed MS Hashemi, **Julien Mazieres**, Tae Min Kim, Elisabeth A. Quoix, Pierre Jean Souquet, Fabrice Barlesi, Christina S Baik, Liza C Villaruz, Ronan Joseph Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson; Institut Gustave Roussy, Thoracic Team, Villejuif, France; Gustave Roussy Université Paris Sud, Villejuif, France; University of Groningen and University Medical Centre Groningen, Groningen, Netherlands; VU University Medical Center, Amsterdam, Netherlands; **Hôpital Larrey CHU Toulouse, Toulouse, France;** Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; University Hospital of Strasbourg, Strasbourg, France; Hôpital de Jour, Pierre Benitef, France; Aix-Marseille

University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, PA; Baylor University Medical Center, Dallas, TX; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA

[Lien vers l'abstract](#)

5. A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.

Authors: Jean-Louis Pujol, Johan F. Vansteenkiste, Luis G. Paz-Ares, Vanesa Gregorc, **Julien Mazieres**, Mark M. Awad, Pasi A. Janne, Michael Jon Chisamore, Anwar Hossain, Yanyun Chen, Joseph Thaddeus Beck; Centre Hospitalier Universitaire, Maladies Respiratoires, Montpellier, France; Gasthuisberg University Hospital, Leuven, Belgium; Hospital Universitario 12 de Octubre, Madrid, Spain; Department of Oncology, San Raffaele Scientific Institute, Milan, Italy; **IUCT, CHU de Toulouse, Toulouse, France**; Massachusetts General Hospital, Cambridge, MA; Dana-Farber Cancer Institute, Boston, MA; Merck and Co., Kenilworth, NJ; Eli Lilly and Company, Indianapolis, IN; Highlands Oncology Group, Fayetteville, AR

[Lien vers l'abstract](#)

6. Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.

Authors: Simon Baldacci, Virginie Avrillon, Benjamin Besse, Bertrand Mennequier, Michael Duruisseaux, **Julien Mazieres**, Renaud Descourt, Helene Doubre, Pascale Dubray- Longeras, Jacques Cadranel, Denis Moro-Sibilot, Charles Ricordel, Sigolène Galland- Girodet, Isabelle Monnet, Josiane Otto, Sophie Schneider, Pascale Missy, Franck Morin, Virginie Westeel, Nicolas Girard; Thoracic Oncology Department, Lille University Hospital, Lille, France; Department of Thoracic Oncology, Centre Léon Bérard, Lyon, France; Gustave Roussy Cancer Campus, Villejuif, France; Nouvel Hopital Civil-Service de Pneumologie, Strasbourg, France; URCOT, Hospices Civils de Lyon Cancer Institute, Lyon, France; **Toulouse University Hospital, and Paul Sabatier University, Toulouse, France**; CHU Morvan, Brest, France; Hopital Foch, Suresnes, France; Centre Jean Perrin, département d'oncologie médicale et CIC 501 Inserm, Clermont Ferrand, France; AP-HP, Hôpital Tenon, service de Pneumologie; GRC 04 Theranoscan, Sorbonne Université, Paris, France; Unité d'Oncologie Thoracique, Service Hospitalier Universitaire Pneumologie Physiologie Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, Grenoble, France; Unité COSS INSERM U1242-CEM-Université de Rennes 1, Service de Pneumologie-CHU Rennes, Rennes, France; Polyclinique Bordeaux Nord Aquitaine, Service d'Oncologie- Radiothérapie, Bordeaux, France; Service de pneumologie, Centre Hospitalier Intercommunal de Creteil, Creteil, France; Centre Antoine Lacassagne, Service d'Oncologie Médicale, Nice, France; CH De La Côte Basque, Service de Pneumologie, Bayonne, France; Intergroupe Francophone de Cancérologie Thoracique, Paris, France; CHRU Jean Minjot, UMR1098, Besançon, France; Institut Curie, Paris, France

[Lien vers l'abstract](#)

7. Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.

Authors: Xiuning Le, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina

Chiara Garassino, **Julien Mazieres**, Santiago Viteri Ramirez, Helene Senellart, Jan Van Meerbeeck, Niels Reinmuth, Pier Franco Conte, Dariusz Kowalski, Byoung Chul Cho, Josef Straub, Jürgen Scheele, Dilafruz Juraeva, Rolf Bruns, John Heymach, Paul K. Paik; Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; CHU Bordeaux, Service Des Maladies Respiratoires, Bordeaux, France; Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan; Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020–UMR-S 1277-Canther, F-59000, Lille, France; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; **IUCT, CHU de Toulouse, Toulouse, France**; Dr Rosell Oncology Institute, Dexeus University Hospital, QuironSalud Group, Barcelona, Spain; Department of Medical Oncology, Comprehensive Cancer Center, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Department of Pulmonology and Thoracic Oncology, Antwerp University Hospital (UZA), Edegem, Belgium; Thoracic Oncology, Asklepios Lung Clinic, Munich-Gauting, Germany; Department of Surgery, Oncology and Gastroenterology, University of Padova and Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy; Department of Lung Cancer and Thoracic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Translational Medicine, Department of Clinical Biomarkers and Companion Diagnostics, Merck KGaA, Darmstadt, Germany; Global Clinical Development, Merck KGaA, Darmstadt, Germany; Translational Medicine, Department of Oncology Bioinformatics, Merck KGaA, Darmstadt, Germany; Department of Biostatistics, Merck KGaA, Darmstadt, Germany; Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

[Lien vers l'abstract](#)

8. Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.

Authors: Marine Gross-Goupil, Nicolas H. Thurin, Magali Rouyer, Jérémy Jové, Thibaud Haaser, Xavier Rebillard, **Michel Soulie**, Gérard de Pouvourville, Marie Pierrès, Camille Capone, Stéphanie Lamarque, Emmanuelle Bignon, Cécile Droz-Perroteau, Nicholas Moore, Patrick Blin; University Hospital, Bordeaux, France; Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France; Bordeaux University Hospital, Pessac, France; Clinique Beausoleil, Montpellier, France; **Centre Hospitalier Universitaire Rangueil, Toulouse, France**; ESSEC, Cergy-Pontoise, France; Janssen, Issy Les Moulineaux, France; Bordeaux PharmacoEpi, Inserm CIC1401, Univ. Bordeaux, Bordeaux, France; Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, CHU Bordeaux, Bordeaux, France

[Lien vers l'abstract](#)

9. Treatment strategies for thymic carcinoma in a real-life setting: Insights from the rythmic network.

Authors : Nicolas Girard, Arthur Petat, Eric Dansin, Calcagno Fabien, Laurent Greillier, Eric Pichon, Mallorie Kerjouan, Christelle Clément Duchene, Bertrand Mennecier, Virginie Westeel, Francois Thillays, Xavier Quantin, Marylise Ginoux, Youssef Oulkhour, Luc Thiberville, Charles Ricordel, Thierry Molina, Pierre Fournel, **Laurence Bigay-Game**, Benjamin Besse; Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; Hospices Civils de Lyon, Lyon, France; Centre Oscar Lambret, Lille, France; IRFC-CHRU Besançon, Besançon, France; Assistance Publique–Hôpitaux de Marseille, Aix Marseille University, Marseille, France; Centre Hospitalier Universitaire Tours, Tours, France; CHU Rennes, Rennes, France;

Institut de Cancérologie de Lorraine, Nancy, France; Nouvel Hopital Civil- Service de Pneumologie, Strasbourg, France; CHRU Jean Minjot, UMR1098, Besançon, France; ICO René Gauducheau, Pays-De-La-Loire, France; Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France; Centre Hospitalier Unversitaire CAEN, Caen, France; Centre Hospitalier Unversitaire Rouen, Rouen, France; APHP, Paris, France; GFPC (France), Institut de Cancérologie de la Loire, St. Priest En Jarez, France; Centre Hospitalier Unversitaire, Hopital Larrey, Toulouse, France; Gustave Roussy Université Paris Sud, Villejuif, France
[Lien vers l'abstract](#)

10. Does neoadjuvant FOLFOX chemotherapy improve the oncological prognosis of high-risk stage II and III colon cancers ? Three years' follow-up results of the Prodigé 22 phase II randomized multicenter trial.

Authors: Medhi Karoui, Claire Gallois, Guillaume Piessen, Jean-Louis Legoux, Emilie Barbier, Cecile De Chaisemartin, Cedric Lecaille, Olivier Bouché, Hanifa Ammarguella, Francesco Brunetti, Michel Prudhomme, Jean-Marc Regimbeau, Olivier Glehen, Astrid Lièvre, **Guillaume Portier**, Johannes Hartwig, Gael Goujon, Benoît Romain, Come Lepage, Julien Taieb; La pitie Salpetrière Hospital, Paris, France; Hopital Européen Georges Pompidou, Paris, France; University Hospital C. Huriez, Dpt. of Digestive and Oncological Surgery, Inserm UMR-S 1172, Jean-Pierre Aubert Research Center (JPARC) Team, Lille, France; Centre Hospitalier Régional Unversitaire, Orléans, France; FFCD and INSERM UMR1231, Dijon, France; Paoli-Calmettes Institut, Marseille, France; Department of Gastroenterology, Polyclinique Nord Aquitaine, Bordeaux, France; CHU Robert Debré, Reims, France; CH Beauvais, Beauvais, France; Hôpital Henri Mondor, Créteil, France; CHU Nimes, Nimes, France; Department of Digestive and Oncological Surgery, Amiens University Medical Center, Clinical Research Center, Amiens University Medical Center, Unit EA4292, Jules Verne University of Picardie, Amiens, France; Centre Hospitalier Lyon- Sud, Hospices Civils de Lyon, Pierre-Bénite, France; CHU Pontchaillou, Rennes, France; **Hôpital Purpan, Toulouse, France**; Infirmerie Protestante, Caluire ET Cuire, France; Hôpital Bichat, Paris, France; Hôpital Hautepierre, Strasbourg, France; Dijon University Hospital, INSERM U1231, Dijon, France; Hôpital Européen Georges Pompidou, Paris, France
[Lien vers l'abstract](#)

11. Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.

Authors: Luis A. Diaz, Dung T. Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jaeger, Hiroki Hara, Matthew E. Burge, Bert H. O'Neil, Petr Kavan, Takayuki Yoshino, **Rosine Guimbaud**, Hiroya Taniguchi, Elena Elez, Salah-Eddin Al-Batran, Patrick M Boland, Yi Cui, Carlos Alberto Mayo, Patricia Marinello, Thierry Andre; Memorial Sloan Kettering Cancer Center, New York, NY; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; University Hospitals Gasthuisberg Leuven, KU Leuven, Leuven, Belgium; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Saitama Cancer Center, Saitama, Saitama Prefecture, Japan; Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Indiana University Simon Cancer Center, Indianapolis, IN; McGill University, Montréal, QC, Canada; National Cancer Center Hospital East, Kashiwa, Japan; **Centre Hospitalier Rangueil, Toulouse, France**; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain;

Institute of Clinical Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; MSD China, Beijing, China; Merck & Co., Inc., Kenilworth, NJ; Sorbonne University and Saint-Antoine Hospital, Paris, France

[Lien vers l'abstract](#)